Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VC Term Sheets: Liquidation Preference and Participating Preferred

This article was originally published in Start Up

Executive Summary

Arthur Klausner discusses liquidation and participating preferred stock in the third part of his series on VC term sheets.

You may also be interested in...



From Verus to Meritage: A Biotech Prototype for Tough Economic Times

Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.

Why Entrepreneurs Should Care about Provisions that Only Directly Impact the Investors

Financing provisions that appear to only directly affect the various series of preferred stock can in fact impact the company's operations somewhere down the line. Such is the case with pay-to-play, voting rights, and a right of first refusal among investors.

Topics

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel